11h
Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.
Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...
How is one of the world’s largest pharmaceutical companies promoting sustainability and regulatory compliance throughout its extensive supply chain?
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments ...
19h
Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee ...
Johnson & Johnson (NYSE:JNJ), a global healthcare giant, continues to navigate a complex landscape of opportunities and ...
We are not going to be intimidated by those acts of terror to radically shift our way of living,” Mayor Brandon Johnson said. “That’s what individuals who stoke fear into people want to see happen.” ...
Stifel analyst Rick Wise lowered the firm’s price target on Johnson & Johnson to $155 from $170 and keeps a Hold rating on the shares.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback